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In Brief
Using flow cytometry analysis,
followed by iTRAQ technology,
ASC speck(⫹) cells were discovered to be enriched with mitochondrial OxPhos proteins,
which modulate mtROS production and downstream inflammasome activation. Two proteins, NDUFB8 (complex I) and
ATP5B (complex V) are found
associated with local recurrencefree survival in NPC patients.
Multivariate analysis additionally
indicated that NDUFB8 and
ATP5B may serve as markers for
local recurrence. This study experimentally links mitochondrial
OxPhos proteins, inflammasome
activation and clinical outcomes
among NPC patients.

Highlights
• Flow cytometry analysis is used to isolate ASC speck(⫹) NPC cells.
• Proteome analysis of ASC speck(⫹) NPC cells reveals enriched mitochondrial OxPhos proteins.
• OxPhos proteins mediate NLRP3 inflammasome activation through mtROS.
• OxPhos proteins, NDUFB8 and ATP5B are correlated with NPC local recurrence.
Chung et al., 2020, Molecular & Cellular Proteomics 19, 142–154
January 2020 © 2020 Chung et al. Published under exclusive license by The American Society for
Biochemistry and Molecular Biology, Inc.
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Mitochondrial Oxidative Phosphorylation
Complex Regulates NLRP3 Inflammasome
Activation and Predicts Patient Survival in
Nasopharyngeal Carcinoma*□
S

I-Che Chung‡§, Lih-Chyang Chen¶, Ngan-Ming Tsang储**, Wen-Yu Chuang‡‡,
Tzu-Chieh Liao§§, Sheng-Ning Yuan§, Chun-Nan OuYang§, David M. Ojcius¶¶储储‡‡‡,
Chih-Ching Wu§ §§§¶¶¶储储储***, and Yu-Sun Chang‡§储储储‡‡‡‡
We previously reported that tumor inflammasomes play a
key role in tumor control and act as favorable prognostic
markers in nasopharyngeal carcinoma (NPC). Activated
inflammasomes frequently form distinguishable specks
and govern the cellular secretion of IL-1␤. However, we
know little about the biological and biochemical differences between cells with and without apoptosis-associated speck-like protein containing a caspase-recruitment
domain (ASC) speck formation. In this study, we used
proteomic iTRAQ analysis to analyze the proteomes of
NPC cells that differ in their ASC speck formation upon
cisplatin treatment. We identified proteins that were differentially over-expressed in cells with specks, and found
that they fell into two Gene ontology (GO) pathways: mitochondrial oxidative phosphorylation (OxPhos) and
ubiquinone metabolism. We observed up-regulation of
various components of the OxPhos machinery (including
NDUFB3, NDUFB8 and ATP5B), and subsequently found
that these changes lead to mitochondrial ROS (mtROS)
production, which promotes the formation and activation
of NLRP3 inflammasomes and subsequent pyroptosis.
In NPC patients, better local recurrence-free survival was
significantly associated with high-level expression of
NDUFB8 (p ⴝ 0.037) and ATP5B (p ⴝ 0.029), as examined
using immunohistochemistry. However, there were no
significant associations between the expression of
NDUFB8 and ATP5B with overall survival of NPC patients. Together, our results demonstrate that up-regulated mitochondrial OxPhos components are strongly
associated with NLRP3 inflammasome activation in
NPC. Our findings further suggest that high-level ex-

pression of OxPhos components could be markers for
local recurrence and/or promising therapeutic targets in
patients with NPC. Molecular & Cellular Proteomics
19: 142–154, 2020. DOI: 10.1074/mcp.RA119.001808.

Inflammation plays important roles at different stages of
tumorigenesis. A key signal involved in driving acute and
chronic inflammation is controlled by the inflammasome,
which is an inducible cytoplasmic multiprotein complex that
serves as a platform for sensing danger signals in the tumor
microenvironment (1, 2). Various inflammasomes have been
identified. Some comprise intracellular pattern recognition receptors, such as nod-like receptors and AIM2-like receptors,
which can be activated by pathogen-associated molecule
patterns and damage-associated molecule patterns (3). The
apoptosis-associated speck-like protein containing a caspaserecruitment domain (ASC)1 protein, also called PYD and CARD
domain containing (PYCARD), is encoded by PYCARD gene in
human and is a key component of all known inflammasomes.
Upon initiation of inflammasome activation, all inflammasomes
recruit the adaptor protein ASC assembles into a large helical
fibril called the ASC speck (4). The ASC speck serves as signaling platform for caspase-1, leading to the activation of
caspase-1, the maturation of pro-inflammatory cytokines (e.g.
IL-1␤) and the initiation of a lytic form of programmed cell death
known as pyroptosis (5).
Nasopharyngeal carcinoma (NPC) is a cancer that is prominent in the Taiwanese population. It is closely associated with
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Epstein-Barr virus (EBV) infection. In tumor cells, EBV-encoded latent membrane protein 1 (LMP1) mediates pro-IL-1␤
gene expression through NF-B signaling (6). Within the NPC
tumor mass or tumor microenvironment, the levels of proinflammatory cytokines, including IL-1␤, are elevated (7). Indeed, elevated levels of IL-1␤ and the NLRP3, AIM2 and RIG-I
inflammasomes were reported to be useful as prognostic
biomarkers for predicting better recurrence-free survival of
NPC patients treated with the current protocols (6). Endbinding protein 1 (EB1), which regulates microtubule polymerization, was reported to co-immunoprecipitate with ASC of
the NLRP3, AIM2, and RIG-I inflammasomes in NPC cells
and was found to be required for speck formation in response to AIM2 inflammasome activation (8). EB1 has also
been shown to mediate the autophagy-dependent secretion
of IL-1␤, and the EB1-mediated, autophagy-based and inflammasome-induced secretion of IL-1␤ was found to be
regulated by 5⬘AMP activated protein kinase (9). Other studies found that the NLRP3 inflammasome is activated by
EBV-LMP1 and the chemotherapeutic agent, cisplatin, in
NLRP3-knockdown NPC cells (6, 10). However, we know
relatively little about the changes in other cellular components of activated inflammasomes.
Emerging evidence indicates that mitochondria not only act
as the energy powerhouses of the cell, they also function as
signaling organelles that can activate signal pathways to regulate innate and adaptive immunity (11). Recent studies have
indicated that mitochondrial dysfunctions may crucially modulate NLRP3 inflammasome activation (12). NLRP3 inflammasome activation involves various parameters that can be
altered under mitochondrial dysfunction, such as mitochondrial membrane potential (mt⌬⌿) (13), mitochondrial outer
membrane permeabilization (14), and the levels of mitochondrion-derived molecules [(e.g. mitochondrial ROS (mtROS)
(15), release of mitochondrial DNA (mtDNA) (16), and cardiolipin (17)] and mitochondrion-residing molecules [(e.g. mitochondrial antiviral signaling protein (MAVS) (18) and mitofusin
2 (Mfn2) (19)]. Notably, MAVS and Mfn2 help redistribute
cytosolic NLRP3 to mitochondrial outer membrane and enhance NLRP3 inflammasome activation. Further, mtROS can

1

The abbreviations used are: ASC, apoptosis-associated specklike protein containing a caspase-recruitment domain; CID, collisioninduced dissociations; EB1, end-binding protein 1; EBV, Epstein-Barr
virus; ETC, electron transport chain; FLICA, fluorochrome labeled
inhibitors of caspase-1; GO, Gene ontology; HCD, higher-energy
collision-induced dissociations; IHC, immunohistochemistry; IRB, Institutional Review Board; LDH, lactate dehydrogenase; LMP1, latent
membrane protein 1; MAVS, mitochondrial antiviral signaling protein;
Mfn2, mitofusin 2; mtDNA, mitochondrial DNA; mt⌬⌿: mitochondrial
membrane potential; mtROS, mitochondrial reactive oxygen species;
NPC, nasopharyngeal carcinoma; OxPhos, oxidative phosphorylation; PI, propidium iodide; PYCARD, PYD and CARD domain containing; SD, standard deviation; TEABC, triethylammonium bicarbonate;
TFA, trifluoroacetic acid.
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oxidize mtDNA, leading to further NLRP3 inflammasome
activation.
The electron transport chain (ETC) is in the mitochondrial
inner membrane. It is the major source of oxidative phosphorylation (OxPhos) and is involved in the generation of energy:
oxygen acts as an electron acceptor, and electrons from
NADH and FADH2 generated by glycolysis and the TCA cycle
are used to generate ATP. Through the ETC, protons are
transported across the inner membrane of mitochondria to
generate mt⌬⌿. Mechanistically, the loss of mitochondrial
potential has been associated with the production of mtROS
(15) and changes in cellular Ca2⫹ (20) in the context of NLRP3
inflammasome activation. Moreover, mitochondria are the
major source of cellular ROS (21). Several lines of evidence
support the notion that mtROS activates NLRP3 inflammasome formation and activation. For example, inhibitors of
OxPhos trigger mtROS production, which can lead to NLRP3
inflammasome activation (15). Meanwhile, we previously
showed that the E3 ubiquitin ligase, Cbl, maintains mitochondrial size and reduces mtROS production by suppressing
NLRP3 inflammasome activation (22). Together, the previous
results reveal that mtROS can be an upstream regulator for
NLRP3 inflammasome activation.
Here, we report that mitochondrial OxPhos components are
enriched in ASC speck-positive NPC cells and are likely to
participate in NLRP3 inflammasome activation and cell pyroptosis. Further, the components of OxPhos are highly expressed in tumor cells and significantly correlated with better
post-treatment survival of NPC patients. Our findings further
clarify the molecular mechanisms of mitochondria-mediated
NLRP3 inflammasome activation and suggest that overexpressed OxPhos proteins could prove useful as favorable
markers for local recurrence in NPC patients.
EXPERIMENTAL PROCEDURES

Cell Culture—EBV-positive NPC cell line, NPC-HK1-EBV, and an
EBV-negative NPC cell line, NPC-HK1, were kindly provided by Dr.
S. W. Tsao (Hong Kong University, SAR, China) and cultured as
previously described (6, 23). The NPC-BM1 cell line was established
from a bone marrow biopsy of a female Taiwanese patient with NPC
and cultured as previously described (24). For generation of NPCHK1-ASC-GFP and NPC-BM1-ASC-GFP cells, the NPC-HK1 and
NPC-BM1 cells were transduced with lentiviral particles containing an
ASC-GFP plasmid, using a commercial lentivirus transduction protocol (Sigma-Aldrich, St. Louis, MO). For inflammasome activation, the
cells were treated with 40 M cisplatin (cat# P4393; Sigma-Aldrich),
10 M nigericin (cat# N7143; Sigma-Aldrich), 5 mM ATP (cat# A7699;
Sigma-Aldrich), 200 M monosodium urate (MSU) crystals (cat# tlrlmsu; InvivoGen, San Diego, CA) or 200 M Alum (cat# tlrl-alk; InvivoGen). For mtROS scavenger treatment, the cells were preincubated
with MitoTEMPO (cat# SML0737; Sigma-Aldrich) for 1 h.
Generation and flow cytometric isolation of ASC-GFP speck-forming cells—NPC-HK1-ASC-GFP and NPC-BM1-ASC-GFP cells were
treated with 40 M cisplatin for 24 h (NPC-HK1-ASC-GFP) or 30 h
(NPC-BM1-ASC-GFP), and ASC speck(⫹) and speck(⫺) cells were
isolated by flow cytometry as previously described (22, 25). Briefly,
the transit of ASC-GFP protein into the speck is detected by a
decreased pulse width (W) of emitted fluorescence after the inflam-
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masome activation, and the total amount of ASC-GFP stained per cell
(pulse area, A) was higher in cells with ASC speck. Therefore, low and
high pulse width to pulse area profile (ASC-W:ASC-A profile) were
taken as indicating ASC speck(⫹) cells and ASC speck(⫺) cells, respectively). We then sorted for the presence or absence of ASC-GFP
specks by flow cytometric method.
Sample Preparation for Tryptic Digestion and iTRAQ Labeling—
NPC-HK1-ASC-GFP and NPC-BM1-ASC-GFP cells were isolated by
flow cytometry and lysed in buffer containing 100 mM triethylammonium bicarbonate (TEABC; Sigma-Aldrich) and 0.1% RapiGestTM SF
(Waters Corporation, Milford, MA) on ice for 15 min. The cell lysate
was collected, sonicated on ice and centrifuged at 10,000 ⫻ g for 25
min at 4 °C. The resulting supernatant was used as the cell extract.
Protein concentrations were determined using a Pierce BCA protein
assay kit (Thermo Fisher Scientific, San Jose, CA). For tryptic insolution digestion, 20 g protein of each sample was reduced with
4.8 mM Tris-(2-carboxyethyl)-phosphine (Sigma-Aldrich) and 260 mM
TEABC at 60 °C for 1 h and then alkylated with 9.6 mM methyl
methanethiosulfonate (Sigma-Aldrich) at room temperature for 30
min. The proteins were digested at 37 °C overnight with modified
sequencing-grade porcine trypsin (Promega, Madison, WI) using a
trypsin-to-protein ratio of 1:1 (w/w). Trypsin-digested peptides were
labeled with iTRAQ reagents (AB Sciex, Foster City, CA) according to
the manufacturer’s protocol. The peptides from ASC speck(⫺) and
speck(⫹) cells were labeled with iTRAQ 114 and 115 tags, respectively. For the biological replicates, the iTRAQ 116 and 117 tags were
incubated with peptide samples obtained from different batches of
ASC speck(⫺) and speck(⫹) cells. After incubation for 1 h at room
temperature, the four labeled samples were pooled, frozen and lyophilized to dryness using a Proteomic CentriVap Concentrator System (Labconco, Kansas City, MO).
The peptides were desalted using a ziptip (Merck Millipore, Billerica, MA) packed with Resin-C18 (GE Healthcare, UK). In brief, a
sufficient volume of Resin-C18 (1 l for 10 g of proteins) was packed
into a ziptip. To activate the Resin-C18, the ziptip was sequentially
loaded with 200 l of acetonitrile (Mallinckrodt Baker, Ireland) at
concentrations of 75%, 40 and 3% in 1% trifluoroacetic acid (TFA),
and then centrifuged at 300 rpm for 30 s. This step was repeated
three times to ensure complete activation. Dried iTRAQ-labeled peptide samples were reconstituted with 0.1% TFA to a final protein
concentration of 1 g/l. The reconstituted peptides were loaded into
the ziptip, centrifuged at 300 rpm for 30 s and washed with 3%
acetonitrile in 1% TFA. Finally, the iTRAQ-labeled peptide samples
were eluted from the ziptip with 30%, 50%, and 70% acetonitrile in
1% TFA and dried by vacuum centrifugation.
Peptide Fractionation and LC-MS/MS Analysis—The iTRAQ-labeled peptides were separated using an on-line 2D-HPLC system
(Dionex Ultimate 3000, Thermo Fisher Scientific) and analyzed as
previously described (26). Briefly, peptides (20 g) were resuspended
in 0.1% formic acid (20 l) and desalted using a ziptip home-packed
with C18 resin (5–20 m, LiChroprep RP-18; Merck, Taipei, Taiwan).
The resultant samples were vacuum-dried, reconstituted in 50 l of
buffer A (0.1% formic acid and 30% acetonitrile), and loaded onto the
homemade column (Luna SCX, 5 m, 0.5 ⫻ 180 mm) at a flow rate of
5 l/min for 30 min. The peptides were then eluted with a 0 –100%
gradient of buffer B (0.5 M ammonium chloride, 30% acetonitrile and
0.1% formic acid). The resulting 44 peptide fractions were diluted
in-line prior to being trapped onto the Zorbax 300SB-C18 column
(0.3 ⫻ 5 mm; Agilent Technologies, Wilmington, DE). Each fraction
was then separated on a homemade column (HydroRP 2.5 m, 75
m inner diameter and 20 cm length) with a 15-m tip using buffer C
(acetonitrile containing 0.1% formic acid). A linear gradient of buffer C
(3–28% for 37 min, 28 –50% for 12 min, 50 –95% for 2 min, 95% for
5 min and 3% for 9 min) was applied at a flow rate of 0.3 l/min.
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The LC equipment was connected to the LTQ-Orbitrap ELITE mass
spectrometer (Thermo Fisher Scientific), which was operated using
the Xcalibur software (Version 2.2, Thermo Fisher Scientific). Full-scan
MS was performed in the Orbitrap over a range of 400 to 2000 Da and
a resolution of 60,000 at m/z 400. The ion signals of (Si(CH3)2O)6H⫹ at
m/z 445.120025, 462.146574 and 536.165365 were used for lock
masses and internal calibration. Each 12 data-dependent MS/MS
scan events of six collision-induced dissociations (CID) and six higher-energy collision-induced dissociations (HCD) were followed by one
MS scan for the six most abundant ions in the preview MS scan. The
m/z values selected for MS2 were excluded dynamically for 40 s with
a relative mass window of 1.5 Da. The electrospray voltage was set to
1.8 kV and the temperature of the capillary was set to 220 °C. Automatic gain control was applied to preclude over-filling of the ion trap,
and 1000 ms/2 ⫻ 106 ions, 150 ms/5 ⫻ 103 ions and 300 ms/3 ⫻ 104
ions were set as the maximum accumulated time/ions for the full
scan, CID and HCD, respectively.
Sequence Database Searching and Quantitative Data Analysis—
Protein database searching was performed using the Proteome Discoverer software (version 1.4; Thermo Fisher Scientific) with the reporter ion quantifier node for iTRAQ data analysis. The MS/MS
spectra were searched against the Swiss-Prot human sequence database (released 2018/03, selected for Homo sapiens; 20,198 entries)
using the Mascot search engine (version 2.2.0; Matrix Science, London, UK). For peptide identification, one missing tryptic cleavage was
allowed. Mass tolerances of 10 ppm, 0.5 Da and 0.05 Da were
permitted for intact peptide masses, CID fragment ions and HCD
fragment ions, respectively. Oxidized methionine (⫹16 Da) was considered a potential variable modification, and iTRAQ (N-terminal,
⫹144 Da), iTRAQ (K, ⫹144 Da) and methyl methanethiosulfonate (C,
⫹46 Da) were considered fixed modifications. The search results
(peptide-spectrum matches) were filtered for a highly confident peptide identification in Proteome Discoverer to ensure that the overall
false discovery rate was less than 0.01. Identification of epithelial
keratins was excluded. Proteins with single peptide hits were removed. Each quantified protein contained at least two quantifiable
spectra. The quantitative data were exported from Proteome Discoverer and manually normalized such that the log2 of protein ratios
displayed a median value of zero for all peptides in each protein. This
was performed across an entire labeling experiment to correct for any
variation in protein abundance. The cutoff value for determining
whether a protein was considered dysregulated was selected according to a comparison of protein levels between the same ASC speck(⫺)
samples in two different batches. Proteins with a log2 ratio greater
than the mean ratio plus one standard deviation (S.D.) and those with
a log2 ratio less than the mean ratio minus one S.D. were overexpressed and underexpressed, respectively.
RNA Interference—NDUFB3 (sense 5⬘-UGGCU UUGCA AAGAG
UGUUU C-3⬘, 5⬘- CCGCA AUGAA GCUUG GAGAU A-3⬘), NDUFB8
(sense 5⬘-CCAAAG CAGUA UCCUU ACAAU-3⬘, 5⬘-CCUGG CUUUC
AUGAU AUUCA U-3⬘), NDUFB5 (sense 5⬘- GUCAA GCUGA ACUAG
CAGAA A-3⬘, 5⬘-CGAAA GCAAC UCCUG ACAAU U-3⬘), MT-CO2
(sense 5⬘-CCAUC AUCCU AGUCC UCAU-3⬘, 5⬘-GAUCC CUCCC
UUACC AUCAA A-3⬘, 5⬘-GCAAU UCCCG GACGU CUAA-3⬘), ATP5B
(sense 5⬘-GCACA GUAAG GACUA UUGCU A-3⬘, 5⬘-GCGUU UCUUG
UCUCA GCCAU U-3⬘), ATP5H (sense 5⬘- CCCGU GCCAG AGGAU
AAAUA U-3⬘, 5⬘-CCAUU GCUAG UUCCC UGAAA U-3⬘) and ATP5J
(sense 5⬘- GAUCC UAUAC AGAAA CUCUU U-3⬘, 5⬘-GAGGA CCUGU
UGAUG CUAGU U-3⬘) siRNAs were purchased from MDBio (Taipei,
Taiwan). Negative-control siRNA were purchased from Invitrogen
(Carlsbad, CA). Cells were transfected with 50 nM dsRNA duplexes
using jetPRIME (Polyplus Transfection, New York, NY) according to
the manufacturer’s instructions. After 4 h of incubation, the dsRNA
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complexes were removed, and the cells were re-plated in 5 ml of fresh
culture medium.
Western Blotting—Western blot analysis was performed as described previously (22). Briefly, cells were lysed in RIPA buffer containing a protease inhibitor mixture (cat# 04693116001; Roche Applied Science, Indianapolis, IN) on ice for 30 min, followed by
centrifugation (12,000 rpm for 10 min at 4 °C). The protein lysates
were further resolved by SDS-PAGE and transferred to nitrocellulose
membranes (Amersham Biosciences, UK). The membranes were incubated with primary anti-human antibodies against NDUFB8 (1:
1000; cat# HPA003886; Sigma-Aldrich), ATP5D (1:2000; cat# A9929;
ABclonal, Woburn, MA), ATP5J (1:2000; cat# A3751; ABclonal),
ATP5H (1:2000; cat# A4425; ABclonal), NDUFB3 (1:500; cat# SC393351; Santa Cruz Biotechnology, Santa Cruz, CA), DNUFB5 (1:
1000; cat# SC-514245; Santa Cruz Biotechnology), ATP5B (1:1000;
cat# SC-55597; Santa Cruz Biotechnology), ATP5F1 (1:500; cat#
sc-514419; Santa Cruz Biotechnology), GAPDH (1:2000; cat# SC32233; Santa Cruz Biotechnology), actin (1:3000; cat# MAB1501;
Merck Millipore), or MT-CO2 (1:2000; cat# A6404; Invitrogen). The
blots were reacted with an HRP-conjugated secondary antibody (1:
5000; Sigma-Aldrich) and the immunoreactive bands were detected
with the TOOLS Extreme ECL-HRP Substrate (cat# TU-ECL03; Biotools, Taiwan).
IL-1␤ ELISA—Human IL-1␤ in cell culture supernatants was detected using the Human IL-1␤ ELISA Ready-SET-Go Kit (cat# 88 –
7261; eBioscience, San Diego, CA) according to the manufacturer’s
instructions.
MtROS Measurement—MtROS were measured using MitoSox
(cat# M36008, Invitrogen) according to the manufacturer’s protocol
and as previously described (22). The NPC cells were incubated with
MitoSox (5 M) at 37 °C for 20 min and then analyzed by flow
cytometry.
Lactate Dehydrogenase (LDH) Release Assay—LDH levels were
detected in the culture supernatant using an LDH Cytotoxicity detection kit (Takara Bio Inc., Shiga, Japan) according to the manufacturer’s instructions and as previously described (27). Briefly, each culture supernatant was collected, centrifuged at 1200 rpm for 5 min at
4 °C and incubated with substrate. The absorbance of the red formazan product was measured at 490 nm using a SpectraMax M2
microplate reader (Molecular Devices, San Jose, CA). The formula for
calculating the percentage of LDH release was as follows: [(LDH
sample)-(LDH negative control)]/[(LDH positive control)-(LDH negative
control)]. The LDH spontaneously release from untreated cells served
as the LDH negative control, whereas the maximum LDH released
from 2% Triton-X-100-treated cells served as the LDH positive
control.
Determination of Caspase-1 Activity and Pyroptotic Cell Death—
Active caspase-1 was detected using the Fluorochrome Labeled
Inhibitors of Caspase-1 (FLICA, FAM-YVAD-FMK) reagent (Immunochemistry Technologies, Bloomington, MN) according to the manufacturer’s instructions. Pyroptotic cell death was assessed by performing double-staining with FLICA and propidium iodide (PI), followed by
flow cytometry.
Patient Characteristics—This study was conducted according to
the principles expressed in the Declaration of Helsinki and was reviewed and approved by the Institutional Review Board (IRB) of
Chang Gung Medical Foundation, Taoyuan, Taiwan. The specimens
used for immunohistochemistry were harvested from 78 NPC patients
seen at Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan,
from 2003 to 2013. Before sample collection, an IRB-approved informed consent form was signed by each participant. The median age
at diagnosis was 49.7 years (range, 25.5–78.8), and the male-tofemale ratio was ⬃2.4:1. Clinical stage was defined according to the
cancer staging system revised by the 7th edition of American Joint
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Committee on Cancer (AJCC) staging manual. All enrolled patients
completed radiotherapy treatment. Among them, 74 patients had
received additional chemotherapy. Any recurrence occurred at the
primary site was a local recurrence. Local recurrence-free survival
and overall survival was calculated as the time from the initiation of
primary radiotherapy to the date of death or the last follow-up. Patient
characteristics and clinical features are shown in Fig. 5A. The examination and enrolment of patients conducted as previously described
(28).
Immunohistochemistry (IHC)—IHC analysis was performed as previously described (6). We used primary antibodies against NDUFB8
(1:150; cat# HPA003886; Sigma-Aldrich) and ATP5B (1:100; cat#
SC-55597; Santa Cruz Biotechnology). The staining intensity was
classified as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The H
score with combining staining intensity and proportion of positive
cells reflected protein expression and were used to classify the specimens/patients into two categories: “high-level” expression (NDUFB8
scoresⱖ100 and/or ATP5B scoresⱖ130) and “low-level” expression
(NDUFB8 scores⬍100 and/or ATP5B scores⬍130). All cases were
scored by an experienced pathologist.
Experimental Design and Statistical Rationale—For investigation of
the NLRP3 inflammasome activation, NPC cells were treated with
NLRP3-activating stimuli, including the cisplatin, nigericin, ATP, MSU
or Alum. For iTRAQ-based LC-MS/MS analysis, ASC speck(⫺) and
speck(⫹) NPC-HK1-ASC-GFP cells were analyzed in two independent
biological replicates. The cutoff value for determining whether a protein was considered dysregulated was selected according to a comparison of protein levels between the same ASC speck(⫺) samples in
two different batches. Proteins with a log2 ratio greater than the mean
ratio plus one S.D. and those with a log2 ratio less than the mean ratio
minus one S.D. were overexpressed and underexpressed, respectively. The functional enrichment analysis of identified proteins was
predicted on GO terms analysis with the Metacore pathway analysis
package or DAVID Bioinformatics Resources, which calculates enrichment p values in the different types of gene sets. We selected
proteins whose iTRAQ ratios (ASC speck(⫹) cells versus ASC speck(⫺)
cells) were at least 2SD above the mean in two biological duplicates,
and subjected them to further verification using Western blotting.
Additionally, NPC-BM1 cells, another NPC cell line were also used to
investigate the difference in protein profiles between speck(⫹) and
speck(⫺) cells through iTRAQ-based proteomic analysis.
Further, we further investigated whether the candidate proteins are
essential for modulation of NLRP3 inflammasome activation and mitochondrial functions by gene knockdown with siRNA. We assessed
their functions in NLRP3 inflammasome activation (NLRP3-mediated
ASC speck formation, caspase-1 activation, IL-1␤ secretion, and cell
pyroptosis) and mitochondrial activity (mtROS production) in our established cell model that the NLRP3 inflammasome is activated by
cisplatin. Data are presented as the mean ⫾ S.D. of three independent experiments and were analyzed with the Student’s t test. p value
less than 0.05 were considered as significant.
To determine the association between the expression of OxPhos
proteins and clinical pathological parameters in NPC. The specimens
harvested from 78 NPC patients were used for IHC analysis. The
expression levels of target proteins were evaluated by assessing both
the staining intensity and the percentage of staining-positive cells.
Additionally, we looked for the correlation between the protein expression and patient survival. Statistical analysis was done using the
PASW Statistics 18.0.0 statistical software package (SPSS Inc.,
2009), as described previously (22). Survival analysis was performed
using the Kaplan-Meier estimator. The log rank test was used to
compare the survival curves of two groups and calculate the relevant
p value. Multivariate analysis of survival using Cox proportional hazards models was conducted to identified which covariates were in-
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FIG. 1. iTRAQ analysis to identify proteins differentially expressed in NPC-HK1 cells with or without ASC specks. A, NPC-HK1 and
NPC-HK1-EBV cells were treated with cisplatin (40 M), nigericin (10 M), ATP (5 mM), MSU (200 M) or Alum (200 M) for 24 h. The
concentrations of IL-1␤ were measured in the cultured medium of cells by enzyme-linked immunosorbent assay (ELISA). Symbols: *p ⬍ 0.05;
**p ⬍ 0.01. B, The ASC-GFP fusion protein was overexpressed in NPC-HK1 cells. Cell lysates were subjected to Western blotting for ASC
protein and ␤-actin. C, Flow chart of the iTRAQ-based proteomics approach. NPC-HK-1-ASC-GFP cells were treated with cisplatin (40 M) for
24 h, ASC speck-containing cells were isolated by flow cytometry (low and high pulse width (W) to pulse area (A) profile (ASC-W:ASC-A profile)
were taken as indicating ASC speck(⫹) cells and ASC speck(⫺) cells, respectively), and iTRAQ- based quantitative proteomic analysis was
performed. D, A total of 634 proteins were enriched (overexpressed) in speck(⫹) NPC-HK-1-ASC-GFP cells after cisplatin stimulation. E, Pie
chart showing the cellular localization percentages of proteins found to be enriched (overexpressed) in speck(⫹) NPC-HK-1-ASC-GFP cells, as
assessed using the Functional Enrichment Analysis tool (http://www.funrich.org/).
dependently associated with local recurrence-free survival and overall
survival. The relevant p value was calculated after cox regression.
Further, the correlation between the expression levels of NDUFB8 and
ATP5B was evaluated using Pearson’s chi-squared test. A p value
less than 0.05 was considered significant.
RESULTS

Comprehensive Proteomic Analysis of Differentially Expressed Proteins in NPC Cells with or Without ASC Specks—
The inflammasome is a sensory complex that alters the immune system in response to pathogen- and damage-induced
signals. To elucidate the activation of NLRP3 inflammasome
after treatment with NLRP3-activating stimuli, we treated
NPC-HK1 cells with NLRP3 stimuli, including the therapeutic
drug cisplatin, pore-forming toxin nigericin, ATP, MSU crystal
or Alum (6, 29 –31). The secretion of IL-1␤ was significantly
increased in NPC-HK1 cells treated with NLRP3 activators
(left panel in Fig. 1A). Moreover, EBV infection has been
reported to link with NPC, the EBV positive NPC-HK1-EBV
cells were also tested for the inflammasome activation after
treatment with NLRP3 activators (cisplatin, nigericin, ATP,
MSU or Alum). Similar effects on IL-1␤ secretion were ob-
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tained when we used EBV-positive NPC cells (NPC-HK1-EBV)
(right panel in Fig. 1A). The percentage of speck forming cells
were increased in cells treated with cisplatin (from 0.25% to
5.59%), nigericin (from 0.35% to 3.05%), ATP (from 0.47%
to 1.81%), MSU (from 0.19% to 0.70%) or Alum (from 0.16%
to 0.31%) (supplemental Fig. S1).
Previous studies showed that NLRP3 inflammasome function is determined by the homotypic domain interaction-mediated recruitment of proteins to the complex, which results in
the formation of speck-like particles (32). However, the molecular mechanisms involved in NLRP3-ASC speck formation
and inflammasome activation remain unclear. To address this
gap, we herein established NPC-HK1 cells stably expressing
an ASC-GFP fusion protein (hereafter referred to as NPCHK1-ASC-GFP cells) (Fig. 1B). The NPC-HK1-ASC-GFP cells
allowed us to visually monitor ASC speck formation in response to treatment with the various NLRP3 agonists
(supplemental Fig. S1). Additionally, a significant increase of
IL-1␤ secretion were demonstrated in NPC-HK1-ASC-GFP
cells treated with NLRP3 activators (supplemental Fig. S1).
Indeed, cells treated with cisplatin (⬃6% speck(⫹) cells),
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which is often used to treat NPC exhibited higher percentage
of ASC speck formation than other NLRP3 agonists, including
nigericin (3.05%), ATP (1.81%), MSU (0.70%) or Alum (0.31%)
(33) (lower panel in Fig. 1C and supplemental Fig. S1). To
investigate the proteomic differences between the speck(⫹)
and speck(⫺) cells, we isolated these cell populations by flow
cytometry (25) and subjected them to iTRAQ-based proteomic analysis (Fig. 1C). The iTRAQ-based analysis resulted
in 4820 and 4780 proteins which were identified (supplemental Table S1) and quantified (supplemental Table S2), respectively. A total of 634 proteins were found to be enriched
(overexpressed) in speck(⫹) NPC-HK1-ASC-GFP cells after
cisplatin stimulation (Fig. 1D and supplemental Table S3).
Computational prediction revealed that more than 30% of the
proteins enriched in the speck(⫹) cells were involved in mitochondrial functions (Fig. 1E and supplemental Table S4).
These results indicated that mitochondrial proteins may play
crucial roles in regulating NLRP3 inflammasome activation in
NPC cells.
Mitochondrial OxPhos Components Are Enriched in ASC
speck(⫹) NPC Cells—Gene ontology (GO) process network
analysis of the 634 proteins found to be enriched in speck(⫹)
versus speck(⫺) NPC cells revealed that most of them participated in two mitochondrion-based biological pathways: mitochondrial OxPhos (p ⫽ 5.068E-41) and ubiquinone metabolism (p ⫽ 4.440E-18) (Fig. 2A). We also observed that the
levels of OxPhos proteins were higher in ASC speck(⫹) cells
(Fig. 2B). Notably, the proteins found to be significantly enriched in ASC speck(⫹) cells were scattered among all five
complexes of the OxPhos machinery, with higher proportions
distributing to complexes I and V (Fig. 2B). We selected proteins whose iTRAQ ratios (ASC speck(⫹) cells versus ASC
speck(⫺) cells) were at least 2SD above the mean in two
biological duplicates, and subjected them to further verification using Western blotting. In ASC speck(⫹) cells, we detected increased levels of OxPhos-related subunits from
complex I (NDUFB3, NDUFB8, and NDUFB5), complex IV
(MT-CO2) and complex V (ATP5B, ATP5D, ATP5J, ATP5H,
and ATP5F1) (Fig. 2C). Moreover, NPC-BM1 cells, another
NPC cell line, which demonstrated increased IL-1␤ secretion
and ASC speck formation in response to cisplatin stimulation
(supplemental Fig. S2A–S2B) were also used to investigate
the difference in protein profiles between speck(⫹) and
speck(⫺) cells through iTRAQ-based proteomic analysis (supplemental Fig. S2B). The iTRAQ-based analysis resulted in
4803 and 4667 proteins which were identified (supplemental
Table S5) and quantified (supplemental Table S6), respectively. A total of 559 proteins were found to be enriched
(overexpressed) in speck(⫹) NPC-BM1-ASC-GFP cells after
cisplatin stimulation (supplemental Table S7). Consistently,
the results indicated that mitochondrial OxPhos components
are enriched in ASC speck(⫹) NPC-BM1 cells (supplemental
Fig. S2C–S2D and supplemental Table S8). These data
strongly indicate that mitochondrial OxPhos components play
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a pivotal role in NLRP3 inflammasome formation and activation in NPC cells.
NDUFB3, NDUFB8, and ATP5B are Involved in NLRP3 Inflammasome Activation and Cell Pyroptosis—Four proteins
whose levels were ⬎2 fold enriched in speck(⫹) cells
(NDUFB3, NDUFB8, ATP5B and MT-CO2) were further verified by treating NPC-HK1-ASC-GFP cells with gene-specific
siRNAs (Fig. 3A), and then further treating them with cisplatin.
As presented in Fig. 3B, the percentage of ASC-speck(⫹) cells
was significantly reduced in cells treated with siRNAs against
NDUFB3, NDUFB8 and ATP5B, but not MT-CO2 (Fig. 3B). We
used the FLICA reagent, which forms a covalent bond with the
active protease (34), to monitor the activation of caspase-1,
which is a step in the process of inflammasome activation. As
demonstrated in Fig. 3C, the cisplatin-induced activity of
caspase-1 was decreased in NPC-HK1 cells subjected to
knockdown of NDUFB3, NDUFB8 or ATP5B, compared with
cells treated with the control siRNA. Moreover, IL-1␤ secretion was significantly decreased in NDUFB3-, NDUFB8- or
ATP5B-knockdown NPC-HK1 cells compared with control
cells (Fig. 3D). Consistently, similar results were obtained in
NPC-BM1 cells (supplemental Fig. S3A–S3D). In contrast,
siRNAs directed against less strongly enriched proteins (i.e.
NDUFB5, ATP5H or ATP5J) (supplemental Fig. S4A) did not
significantly alter cisplatin-induced ASC speck formation
(supplemental Fig. S4B), caspase-1 activation (supplemental
Fig. S4C) or IL-1␤ secretion (supplemental Fig. S4D). Collectively, these results indicate that mitochondrial NDUFB3,
NDUFB8, and ATP5B participate in modulating NLRP3 inflammasome activation.
To assess pyroptotic cell death, which is a form of lytic
programmed cell death that is triggered by inflammasome
activation, we double stained cells for activated caspase-1
and nuclei (using PI) or assessed their release of LDH (35). As
shown in Fig. 3E, the proportion of activated caspase-1/PI
double-positive NPC-HK1 cells was significantly lower in
NDUFB3-, NDUFB8-, or ATP5B-knockdown cells compared
with control cells following cisplatin-induced inflammasome
activation. Similarly, these knockdown cells exhibited decreased LDH release relative to the siRNA control group (Fig.
3F). Similar results were demonstrated in NPC-BM1 cells
(supplemental Fig. S3E–S3F). Taken together, our results reveal that the mitochondrial OxPhos proteins, NDUFB3,
NDUFB8 and ATP5B, appear to be involved in inflammasome
activation and play important roles in regulating inflammasome-related cell pyroptosis.
NDUFB3, NDUFB8, and ATP5B Activate the NLRP3 Inflammasome by Regulating mtROS Production—Although the
above-described results strongly suggested that the mitochondrial OxPhos proteins are involved in regulating NLRP3
inflammasome activation, the mechanism(s) linking mitochondria to NLRP3 inflammasome activation in NPC cells remained unclear. Studies have shown that the NLRP3 inflammasome is activated by mtROS (36, 37), the mitochondrial
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FIG. 2. Mitochondrial OxPhos components are enriched in ASC speck(ⴙ) NPC cells. NPC-HK1-ASC-GFP cells were treated with cisplatin
(40 M) for 24 h and speck(⫹) and speck(⫺) cells were isolated using flow cytometry. A. GO process network of enriched proteins, as generated
using the Metacore pathway analysis package. Most of the enriched or elevated proteins fell into two pathways: oxidative phosphorylation (p ⫽
5.068E-41) and ubiquinone metabolism (p ⫽ 4.440E-18). B, List of OxPhos protein subunits identified by iTRAQ labeling and LC-MS/MS
analysis. The iTRAQ ratios of 115/114 and 117/116 represent the quantitative ratio between ASC speck(⫹) (labeled with 115 or 117 iTRAQ
reagents) and speck(⫺) (labeled with 114 or 116 iTRAQ reagents) cells. Red boxes indicate proteins with iTRAQ ratios of at least 2SD above
the mean. Yellow boxes indicate proteins with iTRAQ ratios between 1 and 2 S.D. above the mean. Blue boxes indicate proteins that did not
show a change in iTRAQ ratio. White boxes indicate proteins that were not identified in the proteome. Figure adapted from https://
www.wikipathways.org/index.php/Pathway:WP111. C, Cell lysates from ASC speck(⫹) and ASC speck(⫺) NPC-HK1-ASC-GFP cells were used
for Western blot analysis. The ratio of OxPhos proteins were calculated by normalization with GAPDH, with the values from the ASC speck(⫺)
cells set as 1.0.

OxPhos machinery is the major site of mtROS production, and
mitochondrial dysfunctions leads to mtROS elevation (38).
Therefore, we examined the effects of NDUFB3, NDUFB8,
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and ATP5B on the mtROS production triggered by NLRP3
inflammasome activation. Our experiments revealed that the
levels of mtROS were elevated in ASC speck(⫹) NPC-HK1 and
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FIG. 3. NDUFB3, NDUFB8 and
ATP5B are involved in NLRP3 inflammasome activation and cell pyroptosis. NPC-HK1 cells were transfected
with NDUFB3-, NDUFB8-, ATP5B-, MTCO2, or control (Ctrl)- siRNA for 48 h,
treated with cisplatin (40 M) for 24 h
and analyzed for ASC speck formation,
caspase-1 activity, IL-1␤ release and cell
pyroptosis. A, Lysates were collected
from knockdown cells and used for
Western blot analysis. B, The percentages of ASC speck(⫹) cells were quantified from NPC-HK1-ASC-GFP cells by
flow cytometry. C, Activated caspase-1
was determined by staining with YVADFLICA followed by flow cytometry. D,
The levels of IL-1␤ in cell culture supernatants were measured by ELISA. E, The
percentages of pyroptotic cells (FLICApositive/PI-positive cells) were detected
by flow cytometry. F, Supernatant LDH
activity was assessed using an LDH Cytotoxicity Assay Kit and the percentages
of LDH release are presented in a histogram. Symbols: *p ⬍ 0.05; **p ⬍ 0.01.

NPC-BM1 cells as compared with ASC speck(⫺) group (Fig.
4A– 4B), and that caspase-1 activation (Fig. 4C) and pyroptotic cell death (Fig. 4D) were significantly inhibited by pretreatment with the mtROS scavenger, MitoTEMPO. Moreover,
NDUFB3-, NDUFB8- and ATP5B-knockdown NPC cells exhibited significant reductions in cisplatin-induced mtROS
production (Fig. 4E– 4F). Together, these data suggest that
mtROS is an upstream regulator of NLRP3 inflammasome
activation in NPC cells, and that mitochondrial OxPhos proteins may mediate mtROS production in these cells.
Association of NDUFB8 and ATP5B with Better Survival in
NPC Patients—We previously reported that higher levels of
inflammasome protein components (e.g. NLRP3) are significantly correlated with better post-treatment recurrence-free
survival of NPC patients (6). In the present study, we show
that OxPhos proteins are involved in modulating NLRP3 inflammasome activation and pyroptotic cell death in NPC cells.
To examine whether these inflammasome activation-related
OxPhos proteins are associated with clinical pathological parameters, we examined 78 biopsy specimens from NPC patients (for a summary of clinical characteristics, see Fig. 5A).
We performed IHC analysis to assess the expression levels of
NDUFB8 and ATP5B in tumors. We then used the expression
levels of NDUFB8 (upper two panels in Fig. 5B) and ATP5B
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(lower two panels in Fig. 5B) to classify the NPC tumor samples into high- or low-expression groups and analyzed the
association of each group with patient survival. Kaplan-Meier
survival analyses revealed that better local recurrence-free
survival was seen among NPC patients in the high-expression
groups for NDUFB8 (p ⫽ 0.037; left panel in Fig. 5C) and
ATP5B (p ⫽ 0.029; right panel in Fig. 5C). Because our results
indicated that NDUFB8 and ATP5B can modulate NLRP3
inflammasome activation and cell pyroptosis, we investigated
whether their expression levels were correlated, and whether
there was prognostic value in assessing the combined expression of these proteins. Indeed, we found that the expression of NDUFB8 and was positively correlated with that of
ATP5B in NPC tissues (Fig. 5D), and that high-level expression of both NDUFB8 and ATP5B in the tumor was strongly
associated with better local recurrence-free survival of patients (p ⫽ 0.006, Fig. 5E). We next conducted a multivariate
analysis of NDUFB8 and ATP5B expression with clinicopathological features, including tumor (T) stage and node (N)
stage, and found that high-ATP5B expression (p ⫽ 0.047) was
a marker of better local recurrence-free survival (Table I).
Although high-NDUFB8 expression was not an independent
predictor of better local recurrence-free survival in multivariate analysis (p ⬎ 0.05), combined high expression of NDUFB8
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FIG. 4. NDUFB3, NDUFB8 and
ATP5B activate the NLRP3 inflammasome by regulating mtROS production. A, Production of mtROS by cisplatin-treated NPC-HK1-ASC-GFP cells
with or without ASC specks. B, Production of mtROS by cisplatin-treated NPCBM1-ASC-GFP cells with or without
ASC specks. NPC-HK1 cells were pretreated with MitoTEMPO for 1 h and
treated with cisplatin (40 M) for 24 h. C,
Activated caspase-1 was determined by
staining with YVAD-FLICA followed by
flow cytometry; D, The percentages
of pyroptotic (FLICA-positive/PI-positive) cells were detected by flow cytometry. NPC-HK1 (E) and NBC-BM1 cells
(F) were transfected with NDUFB3-,
NDUFB8-, ATP5B-, or control (Ctrl)siRNA for 48 h, treated with cisplatin (40
M) for 24 h (NPC-HK1) or 30 h (NPCBM1), and subjected to analysis of
mtROS production. Symbols: *p ⬍ 0.05;
**p ⬍ 0.01.

and ATP5B served as marker for better local recurrence-free
survival (p ⫽ 0.035). However, Kaplan-Meier survival analyses
(supplemental Fig. S5A–S5C) and multivariate analysis (supplemental Fig. S5D) showed no significant association between the expression of NDUFB8 and ATP5B with overall
survival of NPC patients. Together, the results of our clinical
pathological analysis indicate that NDUFB8 and ATP5B could
potentially be developed as useful biomarkers for local recurrence in NPC.
DISCUSSION

In this report, we demonstrate that mitochondria are linked
to NLRP3 inflammasome activation through mitochondrial
OxPhos proteins. Using flow cytometry analysis and iTRAQ
technology, we isolated ASC speck(⫹) cells and found that
they are enriched with OxPhos proteins, which modulate mitochondrial mtROS production and downstream inflammasome activation. We further found that NDUFB8 (complex
I) and ATP5B (complex V) serve as markers for local recurrence-free survival in NPC patients. This study is the first to
experimentally link mitochondrial OxPhos proteins, inflam-
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masome activation and clinical outcomes among NPC patients (Fig. 6).
ASC speck formation, which is a hallmark for inflammasome activation, can be controlled by various cellular
events, including the phosphorylation or ubiquitination of
ASC molecules (39, 40). We previously demonstrated that
Syk kinase can phosphorylate Pyk2, the phosphorylated
Pyk2 relocalizes to ASC specks upon NLRP3 inflammasome
activation, Pyk2 can directly phosphorylate ASC at Tyr146,
and only phosphorylated ASC can participate in speck formation and trigger IL-1␤ secretion (27). Other reports have
shown that linear ubiquitination assembly complex and
TNFR-associated factor 3 are required for ASC-ubiquitination-mediated assembly of the NLRP3/ASC inflammasome
(41, 42). However, we do not yet fully understand the signaling networks that contribute to assembling and regulating inflammasome speck formation. Here, we comprehensively compared the protein expression patterns of ASC
speck(⫹) and speck(⫺) NPC cells, and found that mitochondrial OxPhos proteins are critical for inflammasome formation and activation in this system. In addition, we found that
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FIG. 5. Association of NDUFB8 and ATP5B with better survival in NPC patients. A, The clinical pathological parameters of the NPC
patients. B, Expression levels of NDUFB8 and ATPT5B proteins in NPC tumor cells. Cells were immunohistochemically stained with
protein-specific antibodies, and the results are demonstrated at 400x magnification. C, Kaplan-Meier survival analysis of local recurrence-free
survival curves for NPC patients with NDUFB8 expression (left panel) or ATP5B expression (right panel). D, Correlation between NDUFB8
expression and ATP5B expression in NPC tissues. E, Kaplan-Meier survival analysis of local recurrence-free survival curves for NPC patients
with combine expression of NDUFB8 and ATP5B. Symbols: *p ⬍ 0.05; **p ⬍ 0.01.

the ASC speck(⫹) NPC cells were enriched for various mitochondrial proteins, including some with functions in cristae formation, fatty acid ␤-oxidation and mitochondrial pro-
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tein import. These data strongly suggest that there is a link
between mitochondrial functions and NLRP3 inflammasome
formation/activation.
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TABLE I
Multivariate analysis of the association between NDUFB8 and ATP5B
expression with local recurrence-free survival of NPC patients
Characteristics
Patients (n ⫽ 49)
T stage (3–4 vs. 1–2)
N stage (2–3 vs. 0–1)
NDUFB8⫹ATP5B (High
vs. Low)
Patients (n ⫽ 78)
T stage (3–4 vs. 1–2)
N stage (2–3 vs. 0–1)
NDUFB8 (High vs. Low)
Patients (n ⫽ 78)
T stage (3–4 vs. 1–2)
N stage (2–3 vs. 0–1)
ATP5B (High vs. Low)

Hazards Ratio
(95% CI)

p value

0.543(0.125–2.367)
1.012(0.230–4.453)
0.102(0.012–0.848)

0.416
0.987
0.035

1.126(0.377–3.359)
1.377(0.444–4.273)
0.324(0.098–1.070)

0.831
0.580
0.065

1.169(0.390–3.503)
1.511(0.489–4.663)
0.269(0.074–0.980)

0.780
0.473
0.047

The Cox proportional hazards model was applied for multivariate
analysis to determine the independence of each prognostic factor.

Mitochondrial dysfunction is a major event in NLRP3 inflammasome activation, as NLRP3 stimuli trigger the mitochondrial OxPhos machinery to increase mtROS and decrease
mt⌬⌿ (13, 15). It is known that OxPhos complexes I, III and IV
form a respiratory supercomplex (43) that plays a key role in
regulating mtROS production (44). OxPhos complex V, which
is a major site for intracellular ATP generation, may also
increase mtROS production; conversely the activity of OxPhos complex V can be disrupted by the specific ATP synthase inhibitor, oligomycin (45). In the present study, we
observed higher levels of OxPhos proteins and mtROS pro-

duction in ASC speck(⫹) NPC cells, suggesting that the former
two parameters are correlated with inflammasome activity.
Our findings are consistent with the previous report that ovarian cancer cell lines with high levels of OxPhos proteins (highOxPhos) displayed higher levels of ROS and enhanced chemosensitivity to platinum salts and taxane, compared with
low-OxPhos cells (46). Thus, the accumulation of high levels
of ROS in high-OxPhos cells is likely to be a key determinant
in activating the NLRP3 inflammasome and thereby increasing the chemosensitivity of cancer cells.
We previously demonstrated that high-level NLRP3 inflammasome expression is correlated with better post-treatment
survival in NPC patients (6), but the mechanism underlying
this effect was unclear. ROS have been positively linked to
NLRP3 inflammasome activation and the initiation, promotion,
progression and metastasis of cancer (47). Various cancer
chemotherapeutics (e.g. cisplatin) alter the mitochondrial-dependent ROS response to trigger cell death by greatly enhancing the mtROS level (48). In the present study, our systematic analysis of OxPhos complex components revealed
that in cisplatin-stimulated NPC cells, NDUFB3, NDUFB8, and
ATP5B modulate mtROS production, leading to NLRP3 inflammasome activation and cell pyroptosis. Importantly, we
observed an apparent correlation between high expression
levels of NDUFB8 and ATP5B in NPC tumor specimens, and
this positive relationship seemed to be correlated with better
survival outcomes in NPC patients. These findings suggest
that NDUFB8 and ATP5B may cooperate in facilitating the
NLRP3 inflammasome-mediated regulation of NPC treatment. Consistent with our findings, higher-level expression of

FIG. 6. Role of mitochondrial OxPhos
proteins in NLRP3 inflammasome activation in NPC. Based on the results of
our comprehensive proteomic and functional studies, we propose that mitochondrial OxPhos components are enriched in
ASC speck-forming NPC cells, enhance
mtROS levels and thereby contribute to
NLRP3 inflammasome formation and activation. High expression levels of OxPhos
components, including NDUFB8 (complex I) and ATP5B (complex V), are correlated with better local recurrence-free survival in NPC patients and thus might
prove useful as markers for NPC local
recurrence.
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ATP5B has been correlated with better survival in gallbladder
cancer (49) and acute myeloid leukemia (50). Therefore, the
previous findings and our present results indicate that NLRP3,
ATPT5B, and NDUFB8 can be regarded as markers for assessment of local recurrence in NPC patients.
In summary, we herein describe a previously unrecognized
mitochondrial OxPhos component/mtROS axis and show that
it modulates NLRP3 inflammasome formation and activation.
We further propose that high-level expression of inflammasome-related OxPhos proteins could be developed as biomarkers for local recurrence in NPC patients and/or targeted
as a new therapeutic strategy against inflammation-associated cancer.
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